Parkinson's disease stopped in animal model

March 2, 2012 By Mark Wheeler in Parkinson's & Movement disorders

(Medical Xpress) -- Millions of people suffer from Parkinson's disease, a disorder of the nervous system that affects movement and worsens over time. As the world's population ages, it's estimated that the number of people with the disease will rise sharply. Yet despite several effective therapies that treat Parkinson's symptoms, nothing slows its progression.

While it's not known what exactly causes the disease, evidence points to one particular culprit: a protein called α-synuclein. The protein, which has been found to be common to all patients with Parkinson's, is thought to be a pathway to the disease when it binds together in "clumps," or aggregates, and becomes toxic, killing the brain's neurons.

Now, scientists at UCLA have found a way to prevent these clumps from forming, prevent their toxicity and even break up existing aggregates.

UCLA professor of neurology Jeff Bronstein and UCLA associate professor of neurology Gal Bitan, along with their colleagues, report the development of a novel compound known as a "molecular tweezer," which in a living animal model blocked α-synuclein aggregates from forming, stopped the aggregates' toxicity and, further, reversed aggregates in the brain that had already formed. And the tweezers accomplished this without interfering with normal brain function.

The research appears in the current online edition of the journal Neurotherapeutics.

There are currently more than 30 diseases with no cure that are caused by protein aggregation and the resulting toxicity to the brain or other organs, including Parkinson's, Alzheimer's and Type 2 diabetes. It is therefore critical, Bronstein said, to find a way to stop this aggregation process. Over the last two decades, researchers and pharmaceutical companies have attempted to develop drugs that would prevent abnormal protein aggregation, but so far, they have had little or no success.

While these aggregates are a natural target for a drug, finding a therapy that targets only the aggregates is a complicated process, Bronstein said. In Parkinson's, for example, the protein implicated in the disorder, α-synuclein, is naturally ubiquitous throughout the brain. 

"Its normal function is not well understood, but it may play a role in aiding communication between neurons," Bronstein said. "The trick, then, is to prevent the α-synuclein aggregates and their toxicity without destroying α-synuclein's normal function, along with, of course, other healthy areas of the brain.

Molecular tweezer
 
Bronstein collaborated with Bitan, who had been working with a particular molecular tweezer he had developed called CLR01. Molecular tweezers are complex molecular compounds that are capable of binding to other proteins. Shaped like the letter "C," these compounds wrap around chains of lysine, a basic amino acid that is a constituent of most proteins.

Working first in cell cultures, the researchers found that CLR01 was able to prevent α-synuclein from forming aggregates, prevent toxicity and even break up existing aggregates.

"The most surprising aspect of the work," Bronstein said, "is that despite the ability of the compound to bind to many proteins, it did not show toxicity or side effects to normal, functioning brain cells."

"We call this unique mechanism 'process-specific,' rather than the common protein-specific inhibition," Bitan added, meaning the compound only attacked the targeted aggregates and nothing else.

The researchers next tried their tweezers in a living animal, the zebrafish, a tropical freshwater fish commonly found in aquariums. The zebrafish is a popular animal for research because it is easily manipulated genetically, develops rapidly and is transparent, making the measurement of biological processes easier.

Using a transgenic zebrafish model for , the researchers added CLR01 and used fluorescent proteins to track the tweezer's effect on the aggregations. They found that, just as in cell cultures, CLR01 prevented α-synuclein aggregation and neuronal death, thus stopping the progression of the disorder in the living animal model.

Being able to prevent α-synuclein from aggregating, prevent toxicity and break up existing aggregates is a very encouraging result, but still, at the end of the day, "we've only stopped Parkinson's in zebrafish," Bronstein said.

"Nonetheless," he said, "all of these benefits of CLR01 were found without any evidence of toxicity. And taken together, CLR01 holds great promise as a new drug that can slow or stop the progression of Parkinson's and related disorders. This takes us one step closer to a cure."

The researchers are already studying CLR01 in a mouse model of Parkinson's and say they hope this will lead to human clinical trials.

Other authors of the study included Shubhangi Prabhudesai, Sharmistha Sinha, Aida Attar, Aswani Kotagiri, Arthur G. Fitzmaurice, Ravi Lakshmanan, Magdalena I. Ivanova, Joseph A. Loo and Mark Stahl, all of UCLA, and Frank-Gerrit Klärner and Thomas Schrader of the University of Duisburg–Essen in Germany.

Provided by University of California Los Angeles search and more info website

4.9 /5 (13 votes)  

Rank 4.9 /5 (13 votes)
Relevant PhysicsForums posts

More news stories

Faulty energy production in brain cells leads to disorders ranging from Parkinson's to intellectual disability

Neuroscientist Patrik Verstreken of VIB (Flanders Institute for Biotechnology) and KU Leuven has shown for the first time that dysfunctional mitochondria in brain cells can lead to learning disabilities. The link between ...

Parkinson's & Movement disorders created May 17, 2013 | popularity 4 / 5 (2) | comments 0

Unleashing the watchdog protein

McGill University researchers have unlocked a new door to developing drugs to slow the progression of Parkinson's disease. Collaborating teams led by Dr. Edward A. Fon at the Montreal Neurological Institute and Hospital -The ...

Parkinson's & Movement disorders created May 09, 2013 | popularity 5 / 5 (1) | comments 0 | with audio podcast

Could eating peppers prevent Parkinson's? Dietary nicotine may hold protective key

New research reveals that Solanaceae—a flowering plant family with some species producing foods that are edible sources of nicotine—may provide a protective effect against Parkinson's disease. The study appearing today ...

Parkinson's & Movement disorders created May 09, 2013 | popularity not rated yet | comments 0

Study reveals probable role of Parkinson's protein in healthy brain

(Medical Xpress)—Researchers at the Stanford University School of Medicine have exposed the possible function, in the healthy brain, of a mysterious molecule that has been strongly implicated in Parkinson's ...

Parkinson's & Movement disorders created May 01, 2013 | popularity 5 / 5 (3) | comments 0 | with audio podcast

Study shows how Parkinson's disease protein acts like a virus

A protein known to be a key player in the development of Parkinson's disease is able to enter and harm cells in the same way that viruses do, according to a Loyola University Chicago Stritch School of Medicine study.

Parkinson's & Movement disorders created Apr 25, 2013 | popularity 5 / 5 (5) | comments 0 | with audio podcast


Blame your parents for bunion woes

A novel study reports that white men and women of European descent inherit common foot disorders, such as bunions (hallux valgus) and lesser toe deformities, including hammer or claw toe. Findings from the Framingham Foot ...

Whole-cell vaccine was more effective than acellular vaccine during CA pertussis outbreak

Whole-cell pertussis vaccines were more effective at protecting against pertussis than acellular pertussis vaccines during a large recent outbreak, according to a new Kaiser Permanente study published in Pediatrics.

Treatment of sleep apnea improves glucose levels in prediabetes

Optimal treatment of sleep apnea in patients with prediabetes improves blood sugar (glucose) levels and thus can reduce cardiometabolic risk, according to a study to be presented at the ATS 2013 International Conference in ...

Commonly used catheters double risk of blood clots in ICU and cancer patients

Touted for safety, ease and patient convenience, peripherally inserted central catheters have become many clinicians' go-to for IV delivery of antibiotics, nutrition, chemotherapy, and other medications.

Molecular marker from pancreatic 'juices' helps identify pancreatic cancer

Researchers at Mayo Clinic have developed a promising method to distinguish between pancreatic cancer and chronic pancreatitis—two disorders that are difficult to tell apart. A molecular marker obtained from pancreatic ...

Genetic diversity within tumors predicts outcome in head and neck cancer

A new measure of the heterogeneity – the variety of genetic mutations – of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer. In the May 20 issue ...